DegludecPlus Produced in TEDA Added to List

DegludecPlus, the first double insulin in the world, has been added to the national medical insurance reimbursement list, and will be officially used nationwide on March 1st, 2021. DegludecPlus is developed and produced by Novo Nordisk (China) Pharmaceuticals Co., Ltd. in TEDA.

Novo Nordisk is the world’s leading pharmaceutical company, providing products and services to over 170 countries and regions around the world. Established in 1995, Tianjin Factory is the only supplier of insulin durable injecting devices and an important production base of insulin preparation and filling in Novo Nordisk, which has an important strategic position in the company’s Asia-Pacific planning.